3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
36
Leukemia
32
Myelodysplastic Syndromes
29
Leukemia, Myeloid, Acute
27
Leukemia, Myelomonocytic, Chronic
23
Congenital Abnormalities
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myeloproliferative Disorders
10
Leukemia, Myelomonocytic, Acute
10
Blast Crisis
10
Leukemia, Monocytic, Acute
9
Leukemia, Megakaryoblastic, Acute
9
Leukemia, Erythroblastic, Acute
9
Leukemia, Myeloid, Accelerated Phase
8
Anemia, Refractory
8
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma
7
Thrombocytopenia
6
Leukemia, Myeloid, Chronic-Phase
6
Lymphoma, Non-Hodgkin
5
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Primary Myelofibrosis
4
Neoplasms, Plasma Cell
4
Multiple Myeloma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Hodgkin Disease
4
Interventions
Tretinoin
2
eltrombopag
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Cytarabine
×
Classical hematology
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts